Steffen Sinning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steffen Sinning has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Birgit Schiøtt
Department of Chemistry, Aarhus University, Aarhus, Denmark
12 shared publications Ove Wiborg
From the Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus University Hospital, Skovagervej 2, DK-8240 Risskov, Denmark
10 shared publicationsKasper Severinsen
From the Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus University Hospital, Skovagervej 2, DK-8240 Risskov, Denmark and
9 shared publications- Mikael Bols
Department of Chemistry, University of Copenhagen, DK-2100, Copenhagen Ø, Denmark
8 shared publications Heidi Koldsø
Department of Chemistry, Aarhus University, Denmark; inSPIN & iNANO Centres, Langelandsgade 140, 8000 Aarhus C, Denmark
7 shared publications- Gary Rudnick
Department of Pharmacology, Yale University
4 shared publications
Latest Publications
- Open Access
Antidepressants interact with sex steroid receptors and their intracellular signaling components
There is growing interest in understanding how hormonal signaling pathways contribute to the pathophysiology of mood disorders, based on the premise that fluctuations in sex hormones influence mood, a relationship particularly evident in conditions such as premenstrual dysphoric disorder, prenatal depression, postpartum depression, and perimenopausal depression. Estrogen receptor alpha (ERα) is predominantly localized in the nucleus, but can also be associated with the cell membrane, thus mediating a broad range of genomic and non-genomic effects through distinct intracellular pathways. By employing a combination of computational simulations and in vitro biochemical and cell-based assays, we systematically evaluated the potential binding and functional interactions of antidepressant compounds with ERα. Our results provide compelling evidence that antidepressants may not only affect classical monoaminergic targets but also modulate hormone receptor activity, particularly that of ERα. These findings are consistent with the hypothesis that ERα plays an important role in mood regulation and highlight it as a potential therapeutic target. Moreover, this work raises the possibility that the clinical efficacy of certain antidepressants may, at least in part, derive from their capacity to influence estrogen receptor-mediated signaling. Significance statement: Clinical observations suggest a link between female sex hormones and mood, highlighted by the higher prevalence of depression in women and increased vulnerability to depression during hormonal fluctuations. Here, we report that structurally diverse conventional and rapid-acting antidepressants directly interact with estrogen receptor alpha (ERα). This interaction is associated with rapid intracellular signaling in cellular models. These findings indicate that, alongside their conventional targets, antidepressants may also engage sex steroid receptor components and signaling. This work broadens our basic understanding of antidepressant pharmacology at the cellular level, offering an additional perspective that may inform future research into the biological mechanisms of mood disorders and suggest a framework for developing targeted therapies for hormone-associated depressive disorders.
Open AccessAntidepressants interact with sex steroid receptors and their intracellular signaling components
There is growing interest in understanding how hormonal signaling pathways contribute to the pathophysiology of mood disorders, based on the premise that fluctuations in sex hormones influence mood, a relationship particularly evident in conditions such as premenstrual dysphoric disorder, prenatal depression, postpartum depression, and perimenopausal depression. Estrogen receptor alpha (ERα) is predominantly localized in the nucleus, but can also be associated with the cell membrane, thus mediating a broad range of genomic and non-genomic effects through distinct intracellular pathways. By employing a combination of computational simulations and in vitro biochemical and cell-based assays, we systematically evaluated the potential binding and functional interactions of antidepressant compounds with ERα. Our results provide compelling evidence that antidepressants may not only affect classical monoaminergic targets but also modulate hormone receptor activity, particularly that of ERα. These findings are consistent with the hypothesis that ERα plays an important role in mood regulation and highlight it as a potential therapeutic target. Moreover, this work raises the possibility that the clinical efficacy of certain antidepressants may, at least in part, derive from their capacity to influence estrogen receptor-mediated signaling. Significance statement: Clinical observations suggest a link between female sex hormones and mood, highlighted by the higher prevalence of depression in women and increased vulnerability to depression during hormonal fluctuations. Here, we report that structurally diverse conventional and rapid-acting antidepressants directly interact with estrogen receptor alpha (ERα). This interaction is associated with rapid intracellular signaling in cellular models. These findings indicate that, alongside their conventional targets, antidepressants may also engage sex steroid receptor components and signaling. This work broadens our basic understanding of antidepressant pharmacology at the cellular level, offering an additional perspective that may inform future research into the biological mechanisms of mood disorders and suggest a framework for developing targeted therapies for hormone-associated depressive disorders.
- Open Access
- 19 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
5-HT_FAsTR: a versatile, label-free, high-throughput, fluorescence-based microplate assay to quantify serotonin transport and release
The neurotransmitter serotonin plays a pivotal role in mood and depression. It also acts as a vasoconstrictor within blood vessels and is the main neurotransmitter in the gastrointestinal system. In neurotransmission, released serotonin is taken up by serotonin transporters, which are principal targets of antidepressants and the psychostimulant, ecstasy. The investigation of serotonin transporters have relied almost exclusively on the use of radiolabeled serotonin in heterogenous end-point assays. Here we adapt the genetically encoded fluorescent biosensor, iSeroSnFR, to establish and validate the Serotonin (5-HT) Fluorescence Assay for Transport and Release (5-HT_FAsTR) for functional and pharmacological studies of serotonin transport and release. We demonstrate the applicability of the method for the study of a neuronal, high-affinity, low-capacity serotonin transporter (SERT) as well as an extraneuronal low-affinity, high-capacity organic cation transporter and mutants thereof. 5HT_FAsTR offers an accessible, versatile and reliable semi-homogenous assay format that only relies on a fluorescence plate reader for repeated, real-time measurements of serotonin influx and efflux. 5HT_FAsTR accelerates and democratizes functional characterization and pharmacological studies of serotonin transporters and genetic variants thereof in disease states such as depression, anxiety and ADHD.
- 19 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-16
Open Access5-HT_FAsTR: a versatile, label-free, high-throughput, fluorescence-based microplate assay to quantify serotonin transport and release
The neurotransmitter serotonin plays a pivotal role in mood and depression. It also acts as a vasoconstrictor within blood vessels and is the main neurotransmitter in the gastrointestinal system. In neurotransmission, released serotonin is taken up by serotonin transporters, which are principal targets of antidepressants and the psychostimulant, ecstasy. The investigation of serotonin transporters have relied almost exclusively on the use of radiolabeled serotonin in heterogenous end-point assays. Here we adapt the genetically encoded fluorescent biosensor, iSeroSnFR, to establish and validate the Serotonin (5-HT) Fluorescence Assay for Transport and Release (5-HT_FAsTR) for functional and pharmacological studies of serotonin transport and release. We demonstrate the applicability of the method for the study of a neuronal, high-affinity, low-capacity serotonin transporter (SERT) as well as an extraneuronal low-affinity, high-capacity organic cation transporter and mutants thereof. 5HT_FAsTR offers an accessible, versatile and reliable semi-homogenous assay format that only relies on a fluorescence plate reader for repeated, real-time measurements of serotonin influx and efflux. 5HT_FAsTR accelerates and democratizes functional characterization and pharmacological studies of serotonin transporters and genetic variants thereof in disease states such as depression, anxiety and ADHD.
- Open Access
- 18 March 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (7) , 1298-1320
Serotonin Signaling through Lipid Membranes
Serotonin (5-HT) is a vital modulatory neurotransmitter responsible for regulating most behaviors in the brain. An inefficient 5-HT synaptic function is often linked to various mental disorders. Primarily, membrane proteins controlling the expression and activity of 5-HT synthesis, storage, release, receptor activation, and inactivation are critical to 5-HT signaling in synaptic and extra-synaptic sites. Moreover, these signals represent information transmission across membranes. Although the lipid membrane environment is often viewed as fairly stable, emerging research suggests significant functional lipid-protein interactions with many synaptic 5-HT proteins. These protein-lipid interactions extend to almost all the primary lipid classes that form the plasma membrane. Collectively, these lipid classes and lipid-protein interactions affect 5-HT synaptic efficacy at the synapse. The highly dynamic lipid composition of synaptic membranes suggests that these lipids and their interactions with proteins may contribute to the plasticity of the 5-HT synapse. Therefore, this broader protein-lipid model of the 5-HT synapse necessitates a reconsideration of 5-HT's role in various associated mental disorders.
- 18 March 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (7) , 1298-1320
Open AccessSerotonin Signaling through Lipid Membranes
Serotonin (5-HT) is a vital modulatory neurotransmitter responsible for regulating most behaviors in the brain. An inefficient 5-HT synaptic function is often linked to various mental disorders. Primarily, membrane proteins controlling the expression and activity of 5-HT synthesis, storage, release, receptor activation, and inactivation are critical to 5-HT signaling in synaptic and extra-synaptic sites. Moreover, these signals represent information transmission across membranes. Although the lipid membrane environment is often viewed as fairly stable, emerging research suggests significant functional lipid-protein interactions with many synaptic 5-HT proteins. These protein-lipid interactions extend to almost all the primary lipid classes that form the plasma membrane. Collectively, these lipid classes and lipid-protein interactions affect 5-HT synaptic efficacy at the synapse. The highly dynamic lipid composition of synaptic membranes suggests that these lipids and their interactions with proteins may contribute to the plasticity of the 5-HT synapse. Therefore, this broader protein-lipid model of the 5-HT synapse necessitates a reconsideration of 5-HT's role in various associated mental disorders.
- Open Access
- 18 August 2023
- Published by Springer Nature in Research Square
5-HT_FAsTR: A versatile, label-free, microplate assay to quantify serotonin transport and release using the genetically encoded fluorescent biosensor iSeroSnFR
The neurotransmitter serotonin is important in mood and depression, acts as a vasoconstrictor in blood vessels and is the main neurotransmitter of the gut. In neurotransmission, the released serotonin is taken up by serotonin transporters, which are principal targets of antidepressants and the psychostimulant, ecstasy. Studies of serotonin transporters have relied almost exclusively on the use of radiolabeled serotonin in heterogenous end-point assays. Here we present the establishment and validation of the Serotonin (5-HT) Fluorescence Assay for Transport and Release (5-HT_FAsTR) for functional and pharmacological studies of serotonin transport and release. We demonstrate the applicability of the method for the study of a neuronal, high-affinity, low-capacity serotonin transporter (SERT) as well as an extraneuronal low-affinity, high-capacity organic cation transporter (OCT) and mutants thereof. 5HT_FAsTR is an accessible, versatile and reliable semi-homogenous assay format that only relies on a fluorescence plate reader for repeated, real-time measurements of serotonin influx and efflux.
- 18 August 2023
- Published by Springer Nature in Research Square
Open Access5-HT_FAsTR: A versatile, label-free, microplate assay to quantify serotonin transport and release using the genetically encoded fluorescent biosensor iSeroSnFR
The neurotransmitter serotonin is important in mood and depression, acts as a vasoconstrictor in blood vessels and is the main neurotransmitter of the gut. In neurotransmission, the released serotonin is taken up by serotonin transporters, which are principal targets of antidepressants and the psychostimulant, ecstasy. Studies of serotonin transporters have relied almost exclusively on the use of radiolabeled serotonin in heterogenous end-point assays. Here we present the establishment and validation of the Serotonin (5-HT) Fluorescence Assay for Transport and Release (5-HT_FAsTR) for functional and pharmacological studies of serotonin transport and release. We demonstrate the applicability of the method for the study of a neuronal, high-affinity, low-capacity serotonin transporter (SERT) as well as an extraneuronal low-affinity, high-capacity organic cation transporter (OCT) and mutants thereof. 5HT_FAsTR is an accessible, versatile and reliable semi-homogenous assay format that only relies on a fluorescence plate reader for repeated, real-time measurements of serotonin influx and efflux.
- Open Access
- 1 June 2023
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 53 (5) , 558-569
Nuclear Medicine Preclinical Research: The Role of Cell Cultures
- 1 June 2023
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 53 (5) , 558-569
Open AccessNuclear Medicine Preclinical Research: The Role of Cell Cultures
- 3 March 2021
- Published by Springer Nature in Nature
- Vol. 591 (7851) , 677-681
Structural insights into the inhibition of glycine reuptake
The human glycine transporter 1 (GlyT1) regulates glycine-mediated neuronal excitation and inhibition through the sodium- and chloride-dependent reuptake of glycine1,2,3. Inhibition of GlyT1 prolongs neurotransmitter signalling, and has long been a key strategy in the development of therapies for a broad range of disorders of the central nervous system, including schizophrenia and cognitive impairments4. Here, using a synthetic single-domain antibody (sybody) and serial synchrotron crystallography, we have determined the structure of GlyT1 in complex with a benzoylpiperazine chemotype inhibitor at 3.4 Å resolution. We find that the inhibitor locks GlyT1 in an inward-open conformation and binds at the intracellular gate of the release pathway, overlapping with the glycine-release site. The inhibitor is likely to reach GlyT1 from the cytoplasmic leaflet of the plasma membrane. Our results define the mechanism of inhibition and enable the rational design of new, clinically efficacious GlyT1 inhibitors.
- 3 March 2021
- Published by Springer Nature in Nature
- Vol. 591 (7851) , 677-681
Structural insights into the inhibition of glycine reuptake
The human glycine transporter 1 (GlyT1) regulates glycine-mediated neuronal excitation and inhibition through the sodium- and chloride-dependent reuptake of glycine1,2,3. Inhibition of GlyT1 prolongs neurotransmitter signalling, and has long been a key strategy in the development of therapies for a broad range of disorders of the central nervous system, including schizophrenia and cognitive impairments4. Here, using a synthetic single-domain antibody (sybody) and serial synchrotron crystallography, we have determined the structure of GlyT1 in complex with a benzoylpiperazine chemotype inhibitor at 3.4 Å resolution. We find that the inhibitor locks GlyT1 in an inward-open conformation and binds at the intracellular gate of the release pathway, overlapping with the glycine-release site. The inhibitor is likely to reach GlyT1 from the cytoplasmic leaflet of the plasma membrane. Our results define the mechanism of inhibition and enable the rational design of new, clinically efficacious GlyT1 inhibitors.
- Open Access
- 10 April 2020
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 11 (9) , 1231-1237
A Photoswitchable Inhibitor of the Human Serotonin Transporter
The human serotonin transporter (hSERT) terminates serotonergic signaling through reuptake of neurotransmitter into presynaptic neurons and is a target for many antidepressant drugs. We describe here the development of a photoswitchable hSERT inhibitor, termed azo-escitalopram, that can be reversibly switched between trans and cis configurations using light of different wavelengths. The dark-adapted trans isomer was found to be significantly less active than the cis isomer, formed upon irradiation.
- 10 April 2020
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 11 (9) , 1231-1237
Open AccessA Photoswitchable Inhibitor of the Human Serotonin Transporter
The human serotonin transporter (hSERT) terminates serotonergic signaling through reuptake of neurotransmitter into presynaptic neurons and is a target for many antidepressant drugs. We describe here the development of a photoswitchable hSERT inhibitor, termed azo-escitalopram, that can be reversibly switched between trans and cis configurations using light of different wavelengths. The dark-adapted trans isomer was found to be significantly less active than the cis isomer, formed upon irradiation.
- 1 December 2019
- Published by Elsevier in Neuropharmacology
- Vol. 161, 107548
Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies
- 1 December 2019
- Published by Elsevier in Neuropharmacology
- Vol. 161, 107548
Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies
- 14 June 2019
- Published by H1 Connect
Faculty Opinions recommendation of Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport.
Although transmembrane transporters must convert between conformations that bind and release substrates on opposite sides of the membrane, they often have the annoying property of preferring one of those conformations to the other. Obtaining high-resolution structures of transporters reveals one of the conformations, often leaving the other conformation as a matter of speculation. In these cases, the opposite conformation can sometimes be trapped by covalent cross-linking reagents {1} or by mutating the protein so that it prefers a different conformation than the wild type {2}. In this paper, Coleman et al. describe an inward-open conformation of serotonin transporter (SERT) obtained by another method, which depends on the binding of a conformation preferring inhibitor, ibogaine. This current study is a valuable contribution that provides a much-needed structural context for previous computational and functional studies. Previous results with ibogaine established that its binding to SERT stabilized the protein in an inward-facing conformation in which residues lining the cytoplasmic permeation pathway were accessible to aqueous reagents and residues in the extracellular pathway were protected from the same reagents {3}. In contrast, cocaine and antidepressants stabilize SERT in an outward-facing conformation and have the opposite effect on cytoplasmic and extracellular pathway accessibility {4}. SERT conformation is also sensitive to Na+, which stabilizes outward-facing states, as it does with all members of the SLC6 family of neurotransmitter transporters (5). In this paper, Coleman et al. present four cryo-EM structures of human SERT – three in the presence of ibogaine and one in the presence of paroxetine. All of these structures were obtained with a fragment of antigen binding (Fab) fragment that preserved SERT transport activity, and two of them also contained a single chain variable fragment (scFv) that restricts SERT to outward-facing conformations. Outward-facing structures were obtained when both the Fab and scFv were present, one with paroxetine and one with ibogaine. Although density was observed in the central binding sites of these structures, the resolution was too low to identify ibogaine or paroxetine. However, in the paroxetine structure, the location of the density was consistent with previous X-ray structures {6}. Finding ibogaine in the central binding site of outward-facing SERT was surprising in light of previous studies. Not only was this inhibitor thought to stabilize the inward-open conformation, but ibogaine is known to be a non-competitive inhibitor. Binding to the central site of the outward-facing conformation, ibogaine should compete with serotonin (5-HT), in contrast to its known non-competitive inhibitor mode. However, in these structures, SERT was constrained by the scFv to an outward-open conformation, and the affinity of ibogaine binding under these conditions is 10-fold lower than to unconstrained SERT. Thus, the binding site that ibogaine prefers was not available in the outward-open structure because of the conformational constraint. In the structures obtained with only the Fab fragment, the conformations differed from those obtained together with the scFv. In the presence of ibogaine and NaCl, SERT was found in an occluded conformation with ibogaine in the central binding site, but isolated from a narrowed and truncated extracellular pathway, in part by movement of TM6 towards TM8. When NaCl was replaced with KCl, an inward open conformation was observed, with ibogaine bound in almost the same location but with the extracellular pathway closed further by the movement of TM1b towards TM 10 and the cytoplasmic pathway open due to movement of TM1a away from TM8. This conformational change exposes ibogaine to the cytoplasmic pathway. In previous studies with membranes from SERT-expressing cells, dramatic changes in conformation were observed upon ibogaine addition even in NaCl {3,7}. The requirement shown here for removing Na+ in order to observe the inward-facing structure might reflect the different environment of SERT, which here was in detergent solution, but in previous work was in a cell membrane {3}. The overall conformational change from outward- to inward-facing generally resembles the conversion of LeuT from outward- to inward-open conformations. LeuT, a bacterial amino acid transporter, is the only other member of the SLC6 family for which both inward- and outward-open conformations have been observed {2}. The new paper also shows a structure for SERT with the Fab fragment in KCl with noribogaine (a higher-affinity derivative) at lower resolution. Of all the structures in this paper, the ibogaine-bound inward-facing structure has the highest resolution and the noribogaine structure the lowest, although the conformation of the two structures is similar. One feature of the inward-facing structure is of particular significance. In TM5, residues in the cytoplasmic half of the helix, between G278 and P287 partially unwind, disrupting the helical structure. A similar disruption was observed in an occluded X-ray structure of MhsT, a bacterial SERT homolog {8} and recent models derived from hydrogen-deuterium exchange studies with LeuT {9}. As a consequence, the region containing residues T276 and S277 changed from helical in the outward-facing structure to extend in the inward-facing one – exposing both residues to the cytoplasm. This local conformational change supports observations that reactivity of a cysteine replacing S277 provides a sensitive indication of cytoplasmic pathway opening. Moreover, phosphorylation of T276 regulates SERT activity {10} and treatments that favor the inward-facing SERT conformation increase phosphorylation {7}, consistent with the change in secondary structure observed here. Docking and MD simulations were used to model ibogaine into the rather featureless density found in the central substrate site of the ibogaine-SERT complex. Structurally, ibogaine resembles O-methylated 5-HT with an additional ring system linking the amino group with the indole ring. The general orientation of ibogaine in this model is similar to that demonstrated for 5-HT in a previous study {11} and the ibogaine orientation is also similar to that found by induced-fit docking and molecular dynamics simulation in another publication {12}. Moreover, the orientation of docked ibogaine is similar in the outward-facing, occluded and inward-facing cryo-EM structures. These results suggest that SERT conformational changes do not result in dramatic alterations in the substrate binding site. Nevertheless, the decrease in ibogaine affinity when SERT is restricted to an outward-facing conformation and the observation that ibogaine stabilizes an inward-facing conformation is consistent with an influence of conformational changes on binding site geometry that support increased ibogaine affinity in an inward-facing conformation. The authors propose two mechanisms by which ibogaine could inhibit transport. Ibogaine could bind from the external medium to produce an intermediate like the conformationally restricted outward-facing structure, followed by extracellular pathway closing to form first the occluded NaCl structure and then the inward-facing KCl structure. This possibility is contradicted by the ibogaine inhibition kinetics which are strictly non-competitive in uptake experiments {3,13,14}. Non-competitive inhibition suggests that binding from the outside represents a negligible fraction of the inhibition because ibogaine would have to compete with 5-HT for the central binding site. Slow dissociation of ibogaine might obscure such competition with 5-HT, but this is unlikely because ibogaine dissociates as fast as cocaine, which is a competitive inhibitor {13}. The alternative is that ibogaine could cross the membrane by non-ionic diffusion – it is known to be highly permeant {15} – and bind to SERT from the cytoplasm. However, the cytoplasmic permeation pathway seems too small to allow ibogaine binding without opening wider than shown in this structure and some experiments suggest that cytoplasmic ibogaine does not inhibit SERT {13}. It seems quite likely that ibogaine at the central binding site of SERT is responsible for its conformational influence on the transporter. How it gets there is still a matter for debate.
- 14 June 2019
- Published by H1 Connect
Faculty Opinions recommendation of Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport.
Although transmembrane transporters must convert between conformations that bind and release substrates on opposite sides of the membrane, they often have the annoying property of preferring one of those conformations to the other. Obtaining high-resolution structures of transporters reveals one of the conformations, often leaving the other conformation as a matter of speculation. In these cases, the opposite conformation can sometimes be trapped by covalent cross-linking reagents {1} or by mutating the protein so that it prefers a different conformation than the wild type {2}. In this paper, Coleman et al. describe an inward-open conformation of serotonin transporter (SERT) obtained by another method, which depends on the binding of a conformation preferring inhibitor, ibogaine. This current study is a valuable contribution that provides a much-needed structural context for previous computational and functional studies. Previous results with ibogaine established that its binding to SERT stabilized the protein in an inward-facing conformation in which residues lining the cytoplasmic permeation pathway were accessible to aqueous reagents and residues in the extracellular pathway were protected from the same reagents {3}. In contrast, cocaine and antidepressants stabilize SERT in an outward-facing conformation and have the opposite effect on cytoplasmic and extracellular pathway accessibility {4}. SERT conformation is also sensitive to Na+, which stabilizes outward-facing states, as it does with all members of the SLC6 family of neurotransmitter transporters (5). In this paper, Coleman et al. present four cryo-EM structures of human SERT – three in the presence of ibogaine and one in the presence of paroxetine. All of these structures were obtained with a fragment of antigen binding (Fab) fragment that preserved SERT transport activity, and two of them also contained a single chain variable fragment (scFv) that restricts SERT to outward-facing conformations. Outward-facing structures were obtained when both the Fab and scFv were present, one with paroxetine and one with ibogaine. Although density was observed in the central binding sites of these structures, the resolution was too low to identify ibogaine or paroxetine. However, in the paroxetine structure, the location of the density was consistent with previous X-ray structures {6}. Finding ibogaine in the central binding site of outward-facing SERT was surprising in light of previous studies. Not only was this inhibitor thought to stabilize the inward-open conformation, but ibogaine is known to be a non-competitive inhibitor. Binding to the central site of the outward-facing conformation, ibogaine should compete with serotonin (5-HT), in contrast to its known non-competitive inhibitor mode. However, in these structures, SERT was constrained by the scFv to an outward-open conformation, and the affinity of ibogaine binding under these conditions is 10-fold lower than to unconstrained SERT. Thus, the binding site that ibogaine prefers was not available in the outward-open structure because of the conformational constraint. In the structures obtained with only the Fab fragment, the conformations differed from those obtained together with the scFv. In the presence of ibogaine and NaCl, SERT was found in an occluded conformation with ibogaine in the central binding site, but isolated from a narrowed and truncated extracellular pathway, in part by movement of TM6 towards TM8. When NaCl was replaced with KCl, an inward open conformation was observed, with ibogaine bound in almost the same location but with the extracellular pathway closed further by the movement of TM1b towards TM 10 and the cytoplasmic pathway open due to movement of TM1a away from TM8. This conformational change exposes ibogaine to the cytoplasmic pathway. In previous studies with membranes from SERT-expressing cells, dramatic changes in conformation were observed upon ibogaine addition even in NaCl {3,7}. The requirement shown here for removing Na+ in order to observe the inward-facing structure might reflect the different environment of SERT, which here was in detergent solution, but in previous work was in a cell membrane {3}. The overall conformational change from outward- to inward-facing generally resembles the conversion of LeuT from outward- to inward-open conformations. LeuT, a bacterial amino acid transporter, is the only other member of the SLC6 family for which both inward- and outward-open conformations have been observed {2}. The new paper also shows a structure for SERT with the Fab fragment in KCl with noribogaine (a higher-affinity derivative) at lower resolution. Of all the structures in this paper, the ibogaine-bound inward-facing structure has the highest resolution and the noribogaine structure the lowest, although the conformation of the two structures is similar. One feature of the inward-facing structure is of particular significance. In TM5, residues in the cytoplasmic half of the helix, between G278 and P287 partially unwind, disrupting the helical structure. A similar disruption was observed in an occluded X-ray structure of MhsT, a bacterial SERT homolog {8} and recent models derived from hydrogen-deuterium exchange studies with LeuT {9}. As a consequence, the region containing residues T276 and S277 changed from helical in the outward-facing structure to extend in the inward-facing one – exposing both residues to the cytoplasm. This local conformational change supports observations that reactivity of a cysteine replacing S277 provides a sensitive indication of cytoplasmic pathway opening. Moreover, phosphorylation of T276 regulates SERT activity {10} and treatments that favor the inward-facing SERT conformation increase phosphorylation {7}, consistent with the change in secondary structure observed here. Docking and MD simulations were used to model ibogaine into the rather featureless density found in the central substrate site of the ibogaine-SERT complex. Structurally, ibogaine resembles O-methylated 5-HT with an additional ring system linking the amino group with the indole ring. The general orientation of ibogaine in this model is similar to that demonstrated for 5-HT in a previous study {11} and the ibogaine orientation is also similar to that found by induced-fit docking and molecular dynamics simulation in another publication {12}. Moreover, the orientation of docked ibogaine is similar in the outward-facing, occluded and inward-facing cryo-EM structures. These results suggest that SERT conformational changes do not result in dramatic alterations in the substrate binding site. Nevertheless, the decrease in ibogaine affinity when SERT is restricted to an outward-facing conformation and the observation that ibogaine stabilizes an inward-facing conformation is consistent with an influence of conformational changes on binding site geometry that support increased ibogaine affinity in an inward-facing conformation. The authors propose two mechanisms by which ibogaine could inhibit transport. Ibogaine could bind from the external medium to produce an intermediate like the conformationally restricted outward-facing structure, followed by extracellular pathway closing to form first the occluded NaCl structure and then the inward-facing KCl structure. This possibility is contradicted by the ibogaine inhibition kinetics which are strictly non-competitive in uptake experiments {3,13,14}. Non-competitive inhibition suggests that binding from the outside represents a negligible fraction of the inhibition because ibogaine would have to compete with 5-HT for the central binding site. Slow dissociation of ibogaine might obscure such competition with 5-HT, but this is unlikely because ibogaine dissociates as fast as cocaine, which is a competitive inhibitor {13}. The alternative is that ibogaine could cross the membrane by non-ionic diffusion – it is known to be highly permeant {15} – and bind to SERT from the cytoplasm. However, the cytoplasmic permeation pathway seems too small to allow ibogaine binding without opening wider than shown in this structure and some experiments suggest that cytoplasmic ibogaine does not inhibit SERT {13}. It seems quite likely that ibogaine at the central binding site of SERT is responsible for its conformational influence on the transporter. How it gets there is still a matter for debate.